1 publication

  • Published Subscription Review Article

    Dasatinib Induced Pulmonary Hypertension

    Abstract: Dasatinib (Das) is a second-generation tyrosine kinase inhibitor that is used in the treatment of chronic myelogenous leukemia (CML) in patients who are resistant or intolerant to imatinib, as well as in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. Dasatinib-induced pulmonary arterial hypertension (PAH) is a known but rare adverse effect of dasatinib and is grouped under Group-1 PAH. The mechanism of PAH development is not fully known, but …

    Published in Research and Reviews: A Journal of Pharmacology · Vol. 14, Issue 3, 2024 · pp. 92–95 Read article

Read more of it

Subscribe to one journal or build your own list of several. One invoice, one payment, access for a full year.

Subscribe to journals →

Publish your article

Peer-reviewed journals across every subject, with open access options. Send your manuscript to the right editor today.

Publish with us → Calculate your APC
Support